Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Vinod Ravi, Andrew Scott Brohl, Sant P. Chawla, Steven Attia, Richard F. Riedel, David A. Liebner, Katherine Anne Thornton, Atrayee Basu Mallick, Darren W. Davis, Mario Cervantes, Wen Liu, Keyi Zhu, Delia Alvarez, Charles P. Theuer, Steven Ian Robinson, Nicolas Penel, Silvia Stacchiotti, William D. Tap, Robin Lewis Jones, Robert G. Maki
Institutions: The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, Sarcoma Oncology Center, Mayo Clinic in Florida, Duke Medical Center, The Ohio State University, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Thomas Jefferson University Hospital, NSABP Foundation, Tracon Pharmaceuticals (United States), Mayo Clinic, Centre Oscar Lambret, Fondazione IRCCS Istituto Nazionale dei Tumori, Memorial Sloan Kettering Cancer Center, Institute of Cancer Research, Royal Marsden Hospital, Northwell Health, Cold Spring Harbor Laboratory
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2890739695